Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute st-segment elevation myocardial infarction: Results of the HORIZONS-AMI trial

Catheterization and Cardiovascular Interventions

Volumn 85, Issue 3, 2015, Pages 335-342

  Guerchicoff, Alejandra ^a   Stone, Gregg W ^a,b   Mehran, Roxana ^a,c   Xu, Ke ^a   Nichols, Dru ^a   Claessen, Bimmer E ^d   Guagliumi, Giulio ^e   Witzenbichler, Bernhard ^f   Henriques, Jośe P S ^d   Dangas, George D ^a,c  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^f Helios Amper Kliniken Dachau Department of Cardiology and Pneumology   (Germany)

Author keywords

Acute kidney injury; Angioplasty; Biomarkers; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; CLOPIDOGREL; CXCL CHEMOKINE 23; CYSTATIN C; ENDOTHELIAL CELL SELECTIVE ADHESION MOLECULE; GLYCOPROTEIN IIB INHIBITOR; GLYCOPROTEIN IIIA INHIBITOR; HEPARIN; HIRULOG; PACLITAXEL; PROTEIN INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; AUTACOID; CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEMOSTASIS; HOSPITAL DISCHARGE; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; AGED; BLOOD; BLOOD CLOTTING; EMERGENCY; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UPREGULATION;

ACUTE KIDNEY INJURY; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOMARKERS; BLOOD COAGULATION; CONTRAST MEDIA; EMERGENCIES; FEMALE; FIBRINOLYSIS; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET ACTIVATION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84923046615     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25620     Document Type: Article

References (32)

1. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrastinduced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004;44: 1393-1399.
2. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419-1428.
3. Recio-Mayoral A, Chaparro M, Prado B, Ćozar R, Méndez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus Nacetylcysteine in patients undergoing emergency percutaneous coronary intervention: The RENO study. J Am Coll Cardiol 2007;49:1283-1288.
4. Lazaros G, Tsiachris D, Tousoulis D, Patialiakas A, Dimitriadis K, Roussos D, Vergopoulos E, Tsioufis C, Vlachopoulos C, Stefanadis C. In-hospital worsening renal function is an independent predictor of one-year mortality in patients with acute myocardial infarction. Int J Cardiol 2012;155:97-101.
5. Brown JR, Robb JF, Block CA, Schoolwert AC, Kaplan AV, O'Connor GT, Solomon RJ, Malenka DJ. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv 2010;3:346-350.
6. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL. Contrast volume during primary percutaneous coronary intervention and subsequent contrastinduced nephropathy and mortality. Ann Intern Med 2009;150: 170-177.
7. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with lowosmolar contrast media. JACC Cardiovasc Interv 2009;2:645-654.
8. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB.The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-1548.
9. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, Pichard AD, Satler LF, Wu H, Leon MB. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:409-416.
10. Guitterez N, Diaz A, Timmis GC, Oneill WW, Stevens MA, Sandberg KR, McCullough PA. Determinants of serum creatinine trajectory in acute contrast nephropathy. J Interv Cardiol 2002;15:349-354.
11. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-2204.
12. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with Reevasaculari- ZatiON and Stents in Acute Myocardial Infarction (HORI-ZONS- AMI) trial: Study design and rationale. Am Heart J 2008;156:44-56.
13. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA, Mehta RL. Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. Kidney Int 2006;70:1120-1126.
14. Jarai R, Dangas G, Huber K, Xu K, Brodie BR, Witzenbichler B, Metzger DC, Radke PW, Yu J, Claessen BE, Genereux P, Mehran R, Stone GW. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: A substudy from the HORIZONS-AMI trial. Circ Cardiovasc Interv 2012;5:813-820.
15. Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitax-eleluting stents for treatment of STEMI: A HORIZONS-AMI substudy. J Thromb Thrombolysis 2012;34:165-179.
16. Kikkert WJ, Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques HPS, Tijssen JGP, Sanidas EA, Chantziara V, Xu K, Dangas GD. Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: A HORIZONS-AMI substudy. J Thromb Thrombolysis 2013;35:200-208.
17. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494.
18. Gruberg L, Dangas G, Mehran R, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, Stone GW, Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002;55:66-72.
19. Gruberg L, Rai P, Mintz GS, Canos D, Pinnow E, Satler LF, Pichard AD, Kent KM, Waksman R, Lindsay J, Weissman NJ. Impact of renal function on coronary plaque morphology and morphometry in patients with chronic renal insufficiency as determined by intravascular ultrasound volumetric analysis. Am J Cardiol 2005;96:892-896.
20. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF, Pichard AD, Kent KM, Suddath W, Waksman R. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-343.
21. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. AJR Am J Roentgenol 2003; 181:1463-1471.
22. Kleinegris MCF, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease: A systematic review. Thromb Haemost 2013;110:233-243.
23. Gordge MP, Faint RW, Rylance PB, Ireland H, Lane DA, Neild GH. Plasma D dimer: A useful marker of fibrin breakdown in renal failure. Thromb Haemost 1989;61:522-525.
24. Shibata T, Magari Y, Kamberi P, Ishii T, Tomo T, Yasumori R, Nasu M. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases. Clin Nephrol 1995;44:91-95.
25. Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak M. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: The heart and soul study. Arterioscler Thromb Vasc Biol 2014;34:231-236.
26. Keller C, Katz R, Cushman M, Fried LF, Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: A cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008;9:9.
27. Vaziri ND, Branson HE, Ness R. Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome. Am J Med Sci 1980;280:167-171.
28. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003;107:87-92.
29. Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001;38:189-197.
30. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005; 51:321-327.
31. Brozovic M. Physiological mechanisms in coagulation and fibrinolysis. Br Med Bull 1977;33:231-237.
32. Castillo L, Rohatgi A, Ayers CR, Owens AW, Das SR, Khera A, McGuire DK, de Lemos JA. Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the Dallas Heart Study. J Interferon Cytokine Res 2010;30:339-347.